Mwyngil Therapeutics, a new biotech startup, is tackling obesity with a unique approach that doesn't involve the popular GLP-1 target. CEO Luba Greenwood explains why the company is taking a different path in the multibillion-dollar weight loss market.
A new pilot program will allow some Medicare recipients to access GLP-1 weight loss medications for $50 a month, potentially helping millions of older adults who struggle with obesity. The program, set to launch on July 1, will cover three drugs and be available to those with Medicare Part D who meet certain conditions.
A new government program will make weight loss drugs available to adults 65 and older in Medicare for the first time next month, despite a law prohibiting Medicare from paying for obesity drugs. The program is supposed to be temporary, but may be difficult to end.